Table 2 Internationally approved stem cell drugs
Year | Corporation | Stem cell type | Clinical application | Name of bank |
|---|---|---|---|---|
2009.12 | Prochymal/Osiris Therapeutics, Inc., USA | Mesenchymal stem cells from human allogeneic bone marrow | Graft versus host disease (GVHD) and Crohn’s disease | American Food and Drug Administration (FDA) |
2010.07 | MPC/Mesoblast | Autologous mesenchymal precursor cells | Bone reconstruction | Production permit of Therapeutic Goods Administration (TGA) in Australia |
2011.07 | Hearticellgram-AMI/FCB-Pharmicell | Autologous bone marrow mesenchymal stem cells | Acute myocardial infarction | Food and Drug Administration in South Korea |
2011.11 | Hemacord/New York Blood Center | Cord blood hematopoietic progenitor cells | Hereditary or acquired hematopoietic disease | Biological License of American Food and Drug Administration (FDA) |
2011.11 | MultiStem/Athersys Inc., USA | Allogeneic bone marrow stem cell | Type I mucopolysaccharidosis | American Food and Drug Administration (FDA) |
2012.01 | Cartistem/Medi-post | Mesenchymal stem cells from the cord blood | Degenerative arthritis and cartilage damage in the knee joint | Food and Drug Administration in South Korea |
2012.01 | Cuepistem/Anterogen | Mesenchymal stem cells from autologous fat | Crohn’s disease complicating anal fistula | Food and Drug Administration in South Korea |